DE60017194T2 - Verfahren zur herstellung von carbapenem-antibiotika zubereitungen - Google Patents

Verfahren zur herstellung von carbapenem-antibiotika zubereitungen Download PDF

Info

Publication number
DE60017194T2
DE60017194T2 DE60017194T DE60017194T DE60017194T2 DE 60017194 T2 DE60017194 T2 DE 60017194T2 DE 60017194 T DE60017194 T DE 60017194T DE 60017194 T DE60017194 T DE 60017194T DE 60017194 T2 DE60017194 T2 DE 60017194T2
Authority
DE
Germany
Prior art keywords
temperature
carbapenem
solution
formulation
ampoules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60017194T
Other languages
German (de)
English (en)
Other versions
DE60017194D1 (de
Inventor
Anthony Al-Dehneh
A. William HUNKE
J. Kathleen ILLIG
Anand Kanike
Hiren Patel
D. Scott REYNOLDS
C. Stelios TSINONTIDES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE60017194D1 publication Critical patent/DE60017194D1/de
Publication of DE60017194T2 publication Critical patent/DE60017194T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02—Preparation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
DE60017194T 1999-10-29 2000-10-27 Verfahren zur herstellung von carbapenem-antibiotika zubereitungen Expired - Lifetime DE60017194T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16248299P 1999-10-29 1999-10-29
US162482P 1999-10-29
PCT/US2000/029869 WO2001032172A1 (en) 1999-10-29 2000-10-27 Process for formulation of carbapenem antibiotic compositions

Publications (2)

Publication Number Publication Date
DE60017194D1 DE60017194D1 (de) 2005-02-03
DE60017194T2 true DE60017194T2 (de) 2005-12-22

Family

ID=22585803

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60017194T Expired - Lifetime DE60017194T2 (de) 1999-10-29 2000-10-27 Verfahren zur herstellung von carbapenem-antibiotika zubereitungen

Country Status (8)

Country Link
EP (1) EP1244444B1 (https=)
JP (1) JP4854899B2 (https=)
AT (1) ATE285770T1 (https=)
AU (1) AU770165B2 (https=)
CA (1) CA2388163C (https=)
DE (1) DE60017194T2 (https=)
ES (1) ES2234689T3 (https=)
WO (1) WO2001032172A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548492B1 (en) * 1999-10-29 2003-04-15 Merck & Co., Inc. Process for formulation of carbapenem antibiotic compositions
BR0307518A (pt) * 2002-02-01 2004-12-28 Shimoda Biotech Pty Ltd Composição farmacêutica
EP2505191A1 (en) * 2008-06-11 2012-10-03 Ranbaxy Laboratories Limited Lyophilized Carbapenem antibiotic composition
US8691803B2 (en) 2011-01-24 2014-04-08 Savior Lifetec Corporation Process for the preparation of antibiotic compounds
HK1222339A1 (zh) * 2013-05-07 2017-06-30 Mcmaster University 金属-β-内酰胺酶的抑制剂
KR101587420B1 (ko) * 2014-08-20 2016-01-22 주식회사 대웅제약 에르타페넴-함유 동결건조제제의 제조방법
KR20170014842A (ko) 2015-07-31 2017-02-08 주식회사 대웅제약 개선된 에르타페넴 주사제의 제조방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970281B1 (en) * 1996-05-28 2002-04-30 Merck & Co Inc Carbapenem antibiotic, composition and method of preparation
UA62920C2 (en) * 1996-05-28 2004-01-15 Merck & Co Inc Carbapeneme antibiotic, a composition and a method for the preparation
US6297231B1 (en) * 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
WO1998018800A1 (en) * 1996-10-28 1998-05-07 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
AU726882B2 (en) * 1997-06-16 2000-11-23 Merck Sharp & Dohme Corp. Stabilized carbapenem intermediates and synthetic use

Also Published As

Publication number Publication date
AU1245601A (en) 2001-05-14
CA2388163C (en) 2009-08-25
AU770165B2 (en) 2004-02-12
ES2234689T3 (es) 2005-07-01
JP2003514779A (ja) 2003-04-22
ATE285770T1 (de) 2005-01-15
CA2388163A1 (en) 2001-05-10
EP1244444B1 (en) 2004-12-29
JP4854899B2 (ja) 2012-01-18
DE60017194D1 (de) 2005-02-03
EP1244444A4 (en) 2003-05-21
WO2001032172A1 (en) 2001-05-10
EP1244444A1 (en) 2002-10-02

Similar Documents

Publication Publication Date Title
DE602004010862T2 (de) Zusammensetzungen enthaltend Piperacillin und Tazobactam zur Injektion
DE69232847T2 (de) Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
DE3240177C2 (https=)
DE69333453T2 (de) Kristalline amifostinzusammensetzungen und verfahren für ihre herstellung und ihre verwendung
DE60131441T2 (de) Verfahren zur formulierung antibiotischer verbindungen
DE3729863A1 (de) Stabilisierte erythropoietin-lyophilisate
DE69725696T2 (de) Carbapenem-antibiotikum, zusammensetzung und ihre herstellung
EP0334083B1 (de) Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung
DE60017194T2 (de) Verfahren zur herstellung von carbapenem-antibiotika zubereitungen
DE2752443C2 (de) Verfahren zur Herstellung von Cefazolin-Natrium
US5424069A (en) Production of crystalline penem
EP0806955A1 (de) Enrofloxacin-injektions- oder infusionslösungen
AU2001261079A1 (en) Process for formulation of antibiotic compounds
DD297821A5 (de) Stabilisierte makrolidzusammensetzungen
DE2506622C2 (de) Antibiotisch wirksames Arzneimittel
NZ209111A (en) Lyophilised preparations of 7beta-difluoromethylthioacetamido-7alpha-methoxy-3(1-(2-hydroxyalkyl)-1h-tetrazol-5-yl)-thiomethyl-1dethia-1-oxa-3-cephem-4-carboxylic acid alkali metal salts
DE2920020A1 (de) Pharmazeutisches mittel und verfahren zur herstellung des mittels
DE69400190T2 (de) Verfahren zum herstellen von arzneizusammensetzungen, die vecuroniumbromid enthalten
DE2949485C2 (https=)
US6486150B2 (en) Process for formulation of antibiotic compounds
US4318852A (en) Sodium amoxicillin solvate
KR930001830B1 (ko) 항균성 동결건조 제제
DE19540132C2 (de) Ifosfamid-Lyophilisat
DE4011956A1 (de) Verfahren und vorrichtung zur darstellung von sterilen einspritzbaren antibiotikapulvern
US4898728A (en) Process for production of composition containing lecithin and polyvinylpyrrolidone

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO., INC., RAHWAY, N.J., US

8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 1244444

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 1244444

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213